KLOW peptide: what changed for each drug

The short version: why four studies became one mix

Scientists first studied four short protein chains as separate drugs because they wanted to learn how cells, wounds, and sore tissue repair themselves, and KPV, GHK-Cu, BPC-157, and the thymosin beta-4 protein behind TB-500 each drew interest. Three caused new vessel growth in animals or dishes of cells. New vessels carry oxygen and food to hurt tissue. KPV instead calmed parts of the immune response that cause swelling. Those findings gave researchers a reason to share one vial. What the mix does in your body is still unknown because no one has tested all four together. A mouse result can't predict how you will respond. For every finding, this page tells you the test subject, the change, and the answer that the study still withholds from you.

What KPV changed in a swollen gut

KPV is a tiny part of a hormone, which is a message the body sends. Its parent hormone is a 13-residue protein chain; residue here means one protein building block. In immune cells and cells lining the gut, KPV blocked steps that start swelling ^[3]. The paper used 6 and 8 as lab numbers for two swelling calls. That might help sore tissue settle, but it wasn't a KLOW test.

Gut cells have a small opening that lets KPV enter. Swollen gut cells make more of that opening. Near it, the KPV liquid measured 160 micromolar, a lab measure of the mixture's strength rather than proof of safety for you. Researchers put 100 micromolar KPV, another measure of liquid strength, into the drinking water of mice. Their bowel swelling was less severe. KPV also calmed human gut cells living in lab dishes ^[3]. Mice and cells supplied the results, not people taking KLOW. KPV has no drug approval of its own, so your gut has no approved KPV treatment.

What GHK-Cu changed in skin and wounds

GHK-Cu carries copper and makes up 50 of 80 mg in a common KLOW vial. Loren Pickart first saw GHK in human blood in 1973. Cell work used amounts from 1 to 10 nanomolar, meaning a very small amount mixed into liquid. GHK changed how the cells used their genes, the instructions that tell cells what to make. The paper said 31.2% of the genes it checked changed by at least half ^[5]. Many changes involved collagen, repair, and defenses against cell harm.

Researchers have also put GHK-Cu on human skin. A review saw a collagen rise in 70% of the women who used it. The same change appeared in 50% using vitamin C and 40% using retinoic acid, a vitamin-A skin medicine ^[4]. At age 60, blood held about 80 billionths of one gram for each milliliter. At age 20, blood held about 200 billionths of one gram for each milliliter ^[4]. Those figures don't predict the effect of a shot or KLOW on your skin.

Other work looked at blood vessels. Some copper-holding parts of a body protein made blood-vessel cells multiply in animals and dishes ^[11]. In burned mice, a fat-wrapped form of GHK-Cu closed wounds about 14 days sooner. Treated human blood-vessel cells grew 33.1% more than untreated cells ^[10]. One growth message carried the paper's number 2; it tells blood-vessel cells to grow. KLOW wasn't tested. Copper also helps a body protein fasten collagen to elastin, the springy part of skin. That process can't predict your skin's response.

What BPC-157 changed in blood flow and tendons

BPC-157, or Body Protection Compound 157, is a lab-made 15-amino-acid section of stomach protein, or a chain of protein parts. Researchers first studied it for bowel disease. In cells, BPC-157 made blood-vessel cells respond to a growth message ^[8]. Rats then formed more small vessels and regained blood flow to hurt leg muscle. BPC-157 also changed vessel growth while rat muscle and tendon healed ^[12]. That may explain part of the rat repair, but it doesn't show what would happen in your tendon.

In another study, researchers cut through the Achilles tendon in rats. BPC-157 helped the tendon join, work, and look better under a microscope. That wasn't a test of your knee or shoulder. Doses ran from 10 trillionths of a gram to 10 millionths of a gram per rat ^[2]. Human work is far smaller, so it leaves you with little safety help. In 2025, two healthy adults, a 58-year-old man and a 68-year-old woman, received BPC-157 through a vein. On day 1 they got 10 mg; on day 2 they got 20 mg. Researchers saw no bad event and no clear change in kidney, liver, heart, thyroid, or blood-sugar tests ^[6]. With only 2 people, the study can't show whether BPC-157 works or is broadly safe for you. The drug lacks FDA approval. FDA now places BPC-157 in its withdrawn-nomination table; the earlier Category 2 safety concerns still stand. That entry confers neither FDA approval nor permission to compound.

What TB-500 may change as a wound closes

TB-500 comes from thymosin beta-4, a 43-amino-acid body protein, meaning it is built from a row of protein parts. TB-500 is a brief section cut from that protein. Most good findings arose from separate work on full thymosin beta-4. Researchers can't assume the cut-down drug does all the same work inside you.

In the main wound study, rats received full thymosin beta-4. New skin covered 42% more wound area at 4 days and up to 61% more at 7 days. Wounds pulled shut at least 11% more by day 7. The tissue also made extra collagen as small blood vessels formed. An amount as small as 10 trillionths of a gram made surface skin cells move 2–3-fold, or several times as much, in a dish ^[1]. Cells must move across a wound before they can cover it. Full thymosin beta-4 also helped wounds, hair roots, and vessels in other rodents ^[9].

In a 2025 study, researchers packed full thymosin beta-4 into tiny bubbles made by cells. A wet dressing carried them into a wound, where more blood vessels grew ^[14]. A 2024 review said the full protein also helps the body end its swelling response ^[15]. TB-500 remains banned by WADA.

A 2026 sports medicine review found that TB-500/thymosin beta-4 and BPC-157 looked helpful in animals. Human safety facts remained too sparse to settle the issue for you or your doctor ^[7]. When weighing a TB-500 claim, ask whether the study used the cut-down drug or full protein.

What KLOW research still can't answer

KLOW research has one large gap. No fair study in people or animals has set the four-part mix against one drug, fewer drugs, or a placebo made to resemble care but carrying no active drug. Every teamwork claim rests on separate studies.

Your body gets rid of the drugs at unequal rates. In rats, BPC-157 dropped away in under about 30 minutes. KPV and GHK-Cu may disappear sooner. Less is known about TB-500 than about the larger protein it came from. Sharing a vial won't make their blood levels match in you. The separate study amounts also can't be added and called a KLOW dose for your body.

Copper enters the liquid with GHK-Cu and sits beside the other three drugs. Researchers haven't shown how long that liquid remains usable or whether copper changes the other drugs. These gaps explain why a sound repair idea remains unproved. Until a fair study tests the mix, the separate findings can't prove help from teamwork inside your body.